You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 利好疊加 再鼎醫藥-SB(9688.HK)繼續反彈逾6%
格隆匯5月18日丨再鼎醫藥-SB(9688.HK)延續反彈行情,續升超6%,4日累計漲幅達40%,現報28港元,總市值274億港元。公司引進的Repotrectinib再獲FDA突破性療法認定,這是該藥物獲得的第三項突破性療法認定,再鼎醫藥預計今年Q4將就其上市申請事宜與監管機構進行討論。日前公佈的1Q22收入和淨虧損均好於此前市場預期。浦銀國際指出,公司短期波動後繼續維持“買入”評級,並調整目標價至48 港元。另外,公司未來一年內將迎來眾多臨牀和監管催化劑。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account